Company Overview of Polaris Pharmaceuticals, Inc.
Polaris Pharmaceuticals, Inc. engages in research and development of protein drugs to treat cancer. The company was founded in 2006 and is based in San Diego, California.
9373 Towne Centre Drive
San Diego, CA 92121
Founded in 2006
Key Executives for Polaris Pharmaceuticals, Inc.
Chief Executive Officer and President
Co-Founder and Vice President of Medical Affairs
Executive Vice-President of Regulatory Affairs
Compensation as of Fiscal Year 2015.
Polaris Pharmaceuticals, Inc. Key Developments
Polaris Pharmaceuticals, Inc. Presents at ChinaBio Leadership Retreat 2015, Oct-22-2015
Sep 22 15
Polaris Pharmaceuticals, Inc. Presents at ChinaBio Leadership Retreat 2015, Oct-22-2015 . Venue: Changshu, China.
Polaris Group Announces Treatment of First Patient in Phase 1 Study of ADI-PEG 20 plus FOLFOX
Feb 3 15
Polaris Group announced that the first patient has been dosed in its Phase 1 trial of ADI-PEG 20 in combination with folinic acid (leucovorin), fluorouracil and oxaliplatin (FOLFOX) for the treatment of advanced gastrointestinal malignancies. Â In addition to a global Phase 3 study in hepatocellular carcinoma (HCC) featuring ADI-PEG 20 as a monotherapy, Polaris Group is currently conducting clinical trials on ADI-PEG 20 in combination with cisplatin in melanoma and ovarian cancer, in combination with sorafenib in HCC, in combination with doxorubicin in HER2 negative breast cancer, in combination with nab-paclitaxel and gemcitabine in pancreatic cancer and in combination with cisplatin and pemetrexed in malignant pleural mesothelioma and non-small cell lung carcinoma.
Polaris Group Receives Orphan Drug Designation in United States and European Union for the Treatment of Malignant Pleural Mesothelioma
Dec 18 14
Polaris Group announced that its lead product candidate ADI-PEG 20 has received orphan drug designation for the treatment of malignant pleural mesothelioma in the United States and in the European Union. Orphan drug designation grants special status to a drug or biological product to treat a rare disease or condition. Having completed a successful randomized phase 2 trial in argininosuccinate synthetase -deficient MPM patients with ADI-PEG 20 as monotherapy, Polaris is currently conducting a phase 1 trial of ADI-PEG 20 in combination with pemetrexed and cisplatin, the approved first-line treatment for MPM, for the treatment of MPM and non-squamous non-small cell lung carcinoma. Polaris Group is also conducting clinical trials on ADI-PEG 20, both as monotherapy and in combination with other agents, for the treatment of several other indications, including breast cancer, melanomas, ovarian cancer, and hepatocellular carcinoma. The latter indication is currently in a global Phase 3 study featuring ADI-PEG 20 as a monotherapy.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries